Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment.
Fiche publication
Date publication
octobre 2024
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr EYMARD Jean-Christophe, Dr MOUILLET Guillaume, Dr LORGIS Véronique
Tous les auteurs :
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, Voog E, Eymard JC, Abraham C, Chasseray M, Lorgis V, Hilgers W, Gobert A, Le Moulec S, Simon C, Nicolas E, Escande A, Pouessel D, Mouillet G, Josse C, Solbes MN, Lambert P, Loriot Y
Lien Pubmed
Résumé
Avelumab first-line maintenance treatment was approved for patients with advanced urothelial carcinoma (aUC) without progression following platinum-based chemotherapy (PBC), based on the results from the JAVELIN Bladder 100 phase 3 trial.
Mots clés
Avelumab, Bladder cancer, Immune checkpoint inhibitor, Immunotherapy, Maintenance, Observational study, Real world, Urothelial carcinoma
Référence
Eur Urol Oncol. 2024 10 23;: